electroCore, Inc. (NASDAQ:ECOR – Get Free Report) Director Thomas Errico acquired 5,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were acquired at an average price of $9.85 per share, for a total transaction of $49,250.00. Following the completion of the purchase, the director owned 343,332 shares of the company’s stock, valued at approximately $3,381,820.20. This represents a 1.48% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
electroCore Stock Up 5.3%
Shares of NASDAQ:ECOR opened at $10.81 on Thursday. The firm has a 50 day moving average of $7.72 and a 200 day moving average of $7.13. The company has a market capitalization of $97.51 million, a price-to-earnings ratio of -6.51 and a beta of 0.92. electroCore, Inc. has a 52 week low of $4.41 and a 52 week high of $10.93.
electroCore (NASDAQ:ECOR – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.09. The business had revenue of $9.45 million for the quarter, compared to analysts’ expectations of $9.49 million. electroCore had a negative return on equity of 1,956.38% and a negative net margin of 39.96%. On average, sell-side analysts expect that electroCore, Inc. will post -1.4 EPS for the current year.
Institutional Trading of electroCore
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of electroCore in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, electroCore currently has a consensus rating of “Hold” and an average target price of $18.00.
Check Out Our Latest Analysis on ECOR
electroCore Company Profile
electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.
The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.
Read More
- Five stocks we like better than electroCore
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
